Phase 3 study of pembrolizumab + belzutifan + lenvatinib or pembrolizumab/quavonlimab + lenvatinib versus pembrolizumab + lenvatinib as first-line treatment for advanced renal cell carcinoma Meeting Abstract
| Authors: | Choueiri, T.; Plimack, E.; Powles, T.; Voss, M.; Gurney, H.; Silverman, R.; Perini, R.; Rodriguez-Lopez, K.; Rini, B. |
| Abstract Title: | Phase 3 study of pembrolizumab + belzutifan + lenvatinib or pembrolizumab/quavonlimab + lenvatinib versus pembrolizumab + lenvatinib as first-line treatment for advanced renal cell carcinoma |
| Meeting Title: | 36th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2021) |
| Journal Title: | Journal for ImmunoTherapy of Cancer |
| Volume: | 9 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2021 Nov 10-14 |
| Meeting Location: | Washington, DC |
| ISSN: | 2051-1426 |
| Publisher: | Biomed Central Ltd |
| Date Published: | 2021-11-01 |
| Start Page: | A447 |
| Language: | English |
| ACCESSION: | WOS:000774877500402 |
| DOI: | 10.1136/jitc-2021-SITC2021.417 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 417 -- Meeting was also held virtually -- Source: Wos |
